(Q49322866)

http://europepmc.org/abstract/PMC/5795709

20 February 2018

title

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. (English)

1 reference

http://europepmc.org/abstract/PMC/5795709

20 February 2018

main subject

phase III clinical trial

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Jean-Jacques Grob

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Igor N. Bondarenko

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Luc Thomas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Claus Garbe

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Vanna Chiarion Sileni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Alessandro Testori

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Tai-Tsang Chen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

12

Jedd D Wolchok

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

3

Steinar Aamdal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

11

Marina Tschaika

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

Caroline Robert

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

language of work or name

English

0 references

publication date

23 February 2015

1 reference

http://europepmc.org/abstract/PMC/5795709

20 February 2018

published in

Journal of Clinical Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

1191-1196

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

4 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795709

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795709

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795709

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795709

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795709

Systematic review of medical treatment in melanoma: current status and future prospects.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795709

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795709

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795709

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795709

Evolution of end points for cancer immunotherapy trials.

22 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5795709

14 August 2018

Identifiers

DOI

10.1200/JCO.2014.56.6018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25713437%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

1 reference